Synthesis and discovery of pyrazine-pyridine biheteroaryl as a novel series of potent vascular endothelial growth factor receptor-2 inhibitors

Journal of Medicinal Chemistry

Volumn 48, Issue 6, 2005, Pages 1886-1900

  Kuo, Gee Hong ^a   Wang, Aihua ^a   Emanuel, Stuart ^a   DeAngelis, Alan ^a   Zhang, Rui ^a   Connolly, Peter J ^a   Murray, William V ^a   Gruninger, Robert H ^a   Sechler, Jan ^a   Fuentes Pesquera, Angel ^a   Johnson, Dana ^a   Middleton, Steven A ^a   Jolliffe, Linda ^a   Chen, Xin ^a  

^a Drug Discovery Raritan   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 (3 CHLOROANILINO) 4 [2 (3 HYDROXYPROPYLAMINO) 4 PYRIDYL]PYRIMIDINE; 3 [[4 [6 [(3 CHROLOPHENYL)AMINO]PYRAZIN 2 YL]PYRIDIN 3 YL]AMINO]PROPAN 1 OL; 3 [[5 [5 [(3 CHROLOPHENYL)AMINO] 2 PYRIMIDINYL] 3 PYRIDINYL]AMINO] 1 PROPANOL; 3 [[5 [5 [(3 CHROLOPHENYL)AMINO] 4 PYRIMIDINYL] 3 PYRIDINYL]AMINO] 1 PROPANOL; 3 [[5 [5 [(3 CHROLOPHENYL)AMINO]PYRAZINYL] 3 PYRIDIN YL]AMINO] 1 PROPANOL; 3 [[5 [6 [(3 CHROLOPHENYL)AMINO]PYRAZIN 2 YL]THIAZOL 2 YL]AMINO]PROPAN 1 OL; 3 [[5 [6 [(3 CHROLOPHENYL)AMINO]PYRAZINYL] 3 PYRIDIN YL]AMINO] 1 PROPANOL; 3 [[5 [6 [(3 CHROLOPHENYL)AMINO]PYRIMIDIN 4 YL]PYRIDIN 3 YL]AMINO]PROPAN 1 OL; 3 [[6 [6 [(3 CHROLOPHENYL)AMINO]PYRAZIN 2 YL]PYRIDIN 2 YL]AMINO]PROPAN 1 OL; 3 [[6 [6 [(3 CHROLOPHENYL)AMINO]PYRAZIN 2 YL]PYRIDIN 3 YL]AMINO]PROPAN 1 OL; 3 [[6' [(3 CHROLOPHENYL)AMINO][2,2']BIPYRAZINYL 6 YL]AMINO]PROPAN 1 OL; 3 CHROLOPHENYL[6 [2 [(3 HYDROXYPROPYL)AMINO]OXAZOL 5 YL]PYRAZIN 2 YL]CARBAMIC ACID TERT BUTYL ESTER; CALMODULIN DEPENDENT PROTEIN KINASE II; CASEIN KINASE I; CASEIN KINASE II; CYCLIC AMP DEPENDENT PROTEIN KINASE; CYCLIN DEPENDENT KINASE 4; EPIDERMAL GROWTH FACTOR RECEPTOR; FIBROBLAST GROWTH FACTOR RECEPTOR 2; GLYCOGEN SYNTHASE KINASE 3; INSULIN RECEPTOR KINASE; MITOGEN ACTIVATED PROTEIN KINASE; PLATELET DERIVED GROWTH FACTOR RECEPTOR; PROTEIN KINASE C BETA; PROTEIN KINASE C GAMMA; PYRAZINE DERIVATIVE; PYRIDINE DERIVATIVE; RECEPTOR BLOCKING AGENT; UNCLASSIFIED DRUG; VASCULOTROPIN RECEPTOR 2;

AMINO ACID SEQUENCE; ANGIOGENESIS; AORTA; ARTICLE; CANCER INHIBITION; CATALYSIS; CELL PROLIFERATION; CONTROLLED STUDY; COVALENT BOND; DRUG INHIBITION; DRUG POTENCY; DRUG SELECTIVITY; DRUG SYNTHESIS; ENDOTHELIUM CELL; ENZYME ACTIVITY; ENZYME INHIBITION; HUMAN; HUMAN CELL; IC 50; LUNG FIBROBLAST; SMOOTH MUSCLE FIBER; UMBILICAL VEIN;

ANGIOGENESIS INHIBITORS; CELL PROLIFERATION; CELLS, CULTURED; ENDOTHELIAL CELLS; FIBROBLASTS; HETEROCYCLIC COMPOUNDS, 2-RING; HUMANS; MODELS, MOLECULAR; MUSCLE, SMOOTH, VASCULAR; PYRAZINES; PYRIDINES; UMBILICAL VEINS; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

EID: 20244375346     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm040099a     Document Type: Article

References (74)

1. Risau, W. Mechanism of angiogenesis. Nature 1997, 386, 671-674.
2. Ribatti, D.; Vacca, A.; Nico, B.; Roncali, L.; Dammacco, F. Postnatal angiogenesis. Mech. Devel. 2001, 100, 157-163.
3. (a) Folkman, J. Anti-angiogenesis: New concept for therapy of solid tumors. Ann. Surg. 1972, 175, 409-416.
4. (b) Folkman, J. Tumor angiogenesis: Therapeutic implications. N. Engl. J. Med. 1971, 285, 1182-1186.
5. Spranger, J.; Pfeiffer, A. F. New concepts in pathogenesis and treatment of diabetic retinopathy. Exp. Clin. Endocrinol. Diabetes 2001, 109(Suppl 2), S438-S450.
6. Walsh, D. A.; Haywood, L. Angiogenesis: A therapeutic target in arthritis. Curr. Opin. Investig. Drugs 2001, 2, 1054-1063.
7. McLaren, J.; Prentice, A.; Charnock-Jones, D. S.; Millican, S. A.; Muller, K. H.; Sharkey, A. M.; Smith, S. K. Vascular endothelial growth factor is produced by peritoneal fluid macrophages in endometriosis and is regulated by ovarian steroids. J. Clin. Invest. 1996, 98, 482-489.
8. Detmar, M. Dermatol. Sci. 2000, 24, S78.
9. Folkman, J. What is the evidence that tumors are angiogenesis dependment? J. Natl. Cancer Inst. 1990, 82, 4-6.
10. Liotta, L. A.; Steeg, P. S.; Stetler-Stevenson, W. G. Cancer metastasis and angiogenesis: An imbalance of positive and negative regulation. Cell 1991, 64, 327-336.
11. (a) Nugent, M. A.; Iozzo, R. V. Fibroblast growth factor-2. Int. J. Biochem. Cell. Biol. 2000, 32, 115-120.
12. (b) Carmeliet, P. Mechanisms of angiogenesis and arteriogenesis. Nat. Med. 2000, 6, 389-395.
13. (c) Davis, S.; Yancopoulos, G. D. The angiopoietins: Yin and yang in angiogenesis. Curr. Top. Microbiol. Immunol. 1999, 237, 173-185.
14. (d) Lindahl, P.; Bostrom, H.; Karlsson, L.; Hellstrom, M.; Kalen, M.; Betsholtz, C. Role of plate-derived growth factors in angiogenesis and alveogenesis. Curr. Top. Pathol. 1999, 93, 27-33.
15. (a) Cross, M. J.; Claesson-Welsh, L. FGF and VEGF function in angiogenesis: Signaling pathways, biological responses, and therapeutic inhibition. Trends Pharm. Sci. 2001, 22, 201-207.
16. (b) McMahon, G. VEGF receptor signaling in tumor angiogenesis. Oncologist 2000, 5(Suppl 1), 3-10.
17. (c) Ferrara, N.; Davis-Smyth, T. The biology of vascular endothelial growth factor. Endocr. Rev. 1997, 18, 4-25.
18. De Vries, C.; Escobedo, J. A.; Ueno, H.; Houck, K.; Ferrara, N.; Williams, L. T. The fms-like tyrosine kinase, a receptor for vascular endothelial growth factor. Science 1992, 255, 989-991.
19. (a) Shalaby, F.; Rossant, J.; Yamaguchl, T. P.; Gertsenstein, M.; Wu, X.-F.; Breltman, M. L.; Schuh, A. C. Failure of blood-island formation and vasculogenesis in Flk-1-deficient mice. Nature 1995, 376, 62-66.
20. (b) KDR is human receptor and Flk-1 is mouse receptor.
21. Ferrara, N.; Gerber, H.-P.; LeCouter, J. The biology of VEGF and its receptors. Nat. Med. 2003, 9, 669-676.
22. Kerbel, R. S. A cancer therapy resistant to resistance. Nature (London) 1997, 390, 335-336.
23. Yang, J. C.; Haworth, L.; Sherry, R. M.; Hwu, P.; Schwartzentruber, D. J.; Topalian, S. L.; Steinberg, S. M.; Chen, H. X.; Rosenberg, S. A. A randomized trial of bevacizumab (anti-VEGF antibody) in metastatic renal cancer. N. Eng. J. Med. 2003, 349, 427-434.
24. Prewett, M.; Huber, J.; Li, Y.; Santiago, A.; O'Connor, W.; King, K.; Overholser, J.; Hooper, A.; Pytowski, B.; Witte, L.; Bohlen, P.; Hicklin, D. J. Antivascular endothelial growth factor receptor (fetal liver kinase 1) monoclonal antibody inhibits tumor angiogenesis. Cancer Res. 1999, 59, 5209-5218.
25. Holash, J.; Davis, S.; Papadopoulos, N.; Croll, S. D.; Ho, L.; Russell, M.; Boland, P.; Leidich, R.; Hylton, D.; Burova, E.; Ioffe, E.; Huang, T.; Radziejewski, C.; Baily, K.; Fandl, J. P.; Daly, T.; Wiegand, S. J.; Yancopoulos, G. D.; Rudge, J. S. VEGF-Trap: A VEGF blocker with potent antitumor effects. Proc. Natl. Acad. Sci. U.S.A. 2002, 99, 11393-11398.
26. (a) Drevs, J.; Müller-Driver, R.; Wittig, C.; Fuxius, S.; Esser, N.; Hugenschmidt, H.; Konerding, M. A.; Allegrini, P. R.; Wood, J.; Hennig, J.; Unger, C.; Marmé, D. PTK787/ZK222584, a specific vascular endothelial growth factor-receptor tyrosine kinase inhibitor, effects the anatomy of the tumor vascular bed and the functional vascular properties as detected by dynamic enhanced magnetic resonance imaging. Cancer Res. 2002, 62, 4015-4022.
27. (b) Bold, G.; Altman, K.-H.; Frei, J.; Lang, M.; Manley, P. W.; Traxler, P.; Wietfeld, B.; Brüggen, J.; Buchdunger, E.; Cozens, R.; Ferrari, S.; Furet, P.; Hofmann, F.; Martiny-Baron, G.; Mestan, J.; Rösel, J.; Sills, M.; Stover, D.; Acemoglu, F.; Boss, E.; Emmenegger, R.; Lässer, L.; Masso, E.; Roth, R.; Schlachter, C.; Vetterli, W.; Wyss, D.; Wood, J. M. New anilinophthalazines as potent and orally well absorbed inhibitors of the VEGF receptor tyrosine kinase useful as antagonists of tumor-driven angiogenesis. J. Med. Chem. 2000, 43, 2310-2323.
28. (a) Mendel, D. B.; Laird, A. D.; Xin, X.; Louie, S. G.; Christensen, J. G.; Li, G.; Schreck, R. E.; Abrams, T. J.; Ngai, T. J.; Lee, L. B.; Murray, L. J.; Carver, J.; Chan, E.; Moss, K. G.; Haznedar, J. O.; Sukbuntherng, J.; Blake, R. A.; Sun, L.; Tang, C.; Miller, T.; Shirazian, S.; McMahon, G.; Cherrington, J. M. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: Determination of a pharmacokinetic/pharmacodynamic relationship. Clin. Cancer Res. 2003, 9(1), 327-337.
29. (b) Sepp-Lorenzino, L.; Thomas, K. A. Expert Opin. Invest. Drugs 2002, 11, 1-18.
30. (a) Abdollahi, A.; Lipson, K. E.; Han, X.; Krempien, R.; Trinh, T.; Weber, K. J.; Hahnfeldt, P.; Hlatky, L.; Debus, J.; Howlett, A. R.; Huber, P. E. SU5416 and SU6668 attenuate the angiogenic effects of radiation-induced tumor cell growth factor production and amplify the direct anti-endothelial action of radiation in vitro. Cancer Res. 2003, 63(13), 3755-3763.
31. (b) Sun, Li.; Tran, N.; Liang, C.; Hubbard, S.; Tang, F.; Lipson, K.; Schreck, R.; Zhou, Y.; McMahon, G.; Tang, C. Identification of substituted 3-[(4,5,6,7-tetrahydro-1H-indol-2-yl)methylene]1,3-dihydroindol-2-ones as growth factor receptor inhibitors for VEGF-R2 (Flk-1/KDR), FGF-R1, and PDGF-Rβ tyrosine kinases. J. Med. Chem. 2000, 43, 26655-2663.
32. (a) Ciardiello, F.; Caputo, R.; Damiano, V.; Caputo, R.; Troiani, T.; Vitagliano, D.; Carlomagno, F.; Veneziani, B. M.; Fontanini, G.; Bianco, A. R.; Tortora, G. Antitumor effects of ZD6474, a small molecule vascular endothelial growth factor receptor tyrosine kinase inhibitor, with additional activity against epidermal growth factor receptor tyrosine kinase. Clin. Cancer Res. 2003, 9(4), 1546-1556.
33. (b) Hennequin, L. F.; Stokes, E. S.; Thomas, A. P.; Johnstone, C.; Plé, P. A.; Ogilvie, D. J.; Dukes, M.; Wedge, S. R.; Kendrew, J.; Curwen, J. O. Novel 4-anilino-quinazolines with C-7 basic side chains: Design and structure activity relationship of a series of potent, orally active, VEGF receptor tyrosine kinase inhibitors. J. Med. Chem. 2002, 45, 1300-1312.
34. Kabbinavar, F.; Hurwitz, H. I.; Fehrenbacher, L.; Meropol, N. J.; Novotny, W. F.; Lieberman, G.; Griffing, S.; Bergsland, E. Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J. Clin. Oncol. 2003, 21(1), 60-65.
35. (a) Gingrich, D. E.; Reddy, D. R.;, Iqbal, M. A.; Singh, J.; Almone, L. D.; Angeles, T. S.; Albom, M.; Yang, S.; Ator, M. A.; Meyer, S. L.; Robinson, C.; Ruggeri, B. A.; Dionne, C. A.; Vaught, J. L.; Mallamo, J. P.; Hudkins, R. L. A new class of potent vascular endothelial growth factor receptor tyrosine kinase inhibitors: Structure-activity relationships for a series of 9-alkoxymethyl-12-(3-hydroxypropyl)indeno [2,1-a] pyrrolo [3,4-c] carbazole-5-ones and the identification of CEP-5214 and its dimethylglycine ester prodrug clinical candidate CEP-7055. J. Med. Chem. 2003, 46, 5375-5388.
36. (b) Boyer, S. J. Small molecule inhibitors of KDR (VEGFR-2) kinase: An overview of structure activity relationships. Curr. Top. Med. Chem. 2002, 2, 973-1000.
37. (c) Connell, R. D. Patent focus on cancer chemotherapeutics V. Angiogenesis agents: September 2001-August 2002. Expert Opin. Ther. Pat. 2002, 12, 1763-1782.
38. Wolfe, J. P.; Buchwald, S. L. Palladium-catalyzed amination of aryl triflates. J. Org. Chem. 1997, 62, 1264-1267.
39. Reisch, J.; Dziemba, P.; Mura, M. L.; Rao, A. R. R. Natural product chemistry, part 159 [1]. Two methods for the synthesis of 4-azaacronycine as a potential antitumor agent. J. Heterocycl. Chem. 1993, 30, 981-983.
40. Brown, A. D.; Dickinson, R. P.; Wythes, M. J. Indole derivatives as 5-HT-like agonists WO 93/21178.
41. Farina, V.; Krishnan, B. Large rate accelerations in the Stille reaction with tri-2-furylphosphine and triphenylarsine as palladium ligands: Mechanistic and synthetic implications. J. Am. Chem. Soc. 1991, 113, 9585-9595.
42. Fujita, M.; Oka, H.; Ogura, K. Palladium(0)/LiCl promoted cross-coupling reaction of (4-pyridyl)stannanes and aromatic bromides: Easy access to poly(4-pyridyl)-substituted aromatics. Tetrahedron Lett. 1995, 36, 5247-5250.
43. 2) bond formation: N-Arylation of aromatic and unsaturated nitrogen and the reductive elimination chemistry of palladium azolyl and methyleneamido complexes. J. Am. Chem. Soc. 1998, 120, 827-828.
44. Sato, N.; Fujii, M. Studies on pyrazines. 29 [1]. High regioselective synthesis of choropyrazines from 3-substituted pyrazine 1-oxides. J. Heterocycl. Chem. 1994, 31, 1177-1180.
45. Lohse, O. Improved large-scale preparation of 4-iodopicolinic acid. Synth. Commun. 1998, 26, 2017-2025.
46. Kelly, T. R.; Kim, M. H. Synthesis of schumanniophytine and isoschumanniophvtine. J. Org. Chem. 1992, 57, 1593-1597.
47. (a) Torrado, A.; Lopez, S.; Alvarez, R.; Lera, A. R. General synthesis of retionids and arotinoids via palladium-catalyzed cross-coupling of boronic acids with electrophiles. Synthesis 1995, 285-293.
48. (b) Torrado, A.; Imperiali, B. New synthetic amino acids for the design and synthesis of peptide-based metal ion sensors. J. Org. Chem. 1998, 61, 8940-8948.
49. Aoyagi, Y.; Inoue, A.; Koizumi, I.; Hashimoto, R.; Tokunaga, K.; Gohma, K.; Komatsu, J.; Sekine, K.; Miyafuji, A.; Kunoh, J.; Honma, R.; Akita, Y.; Ohta, A. Palladium-catalyzed cross-coupling reactions of chloropyrazines with aromatic heterocycles. Heterocycles 1992, 33, 257-272.
50. Vedejs, E.; Luchetta, L. M. A method for iodination of oxazoles at C-4 via 2-lithiooxazoles. J. Org. Chem. 1999, 64, 1011-1014.
51. Monaco, E. A., III; Vallano, M. L. Cyclin-dependent kinase inhibitors: Cancer killers to neuronal guardians. Curr. Med. Chem. 2003, 10, 367-379.
52. Senderowicz, A. M. Modulators of cyclin-dependent kinases: A novel therapeutic approach for the treatment of neoplastic diseases. Cell Cycle Inhib. Cancer Ther. 2003, 179-205.
53. Fischer, P. M.; Gianella-Borradori, A. CDK inhibitors in clinical development for the treatment of cancer. Exp. Opin. Invest. Drugs 2003, 12, 955-970.
54. Grant, S.; Roberts, J. D. The use of cyclin-dependent kinase inhibitors alone or in combination with established cytotoxic drugs in cancer chemotherapy. Drug Resistance Updates 2003, 6(1), 15-26.
55. Kelland, L. R. Flavopiridol, the first cyclin-dependent kinase inhibitor to enter the clinic: Current status. Exp. Opin. Invest. Drugs 2000, 9, 2903-2922.
56. Grosios, K. UCN-01 Kyowa Hakko Kogyo Co. Curr. Opin. Invest. Drugs 2001, 2, 287-297.
57. (a) Ruetz, S.; Fabbro, D.; Zimmermann, J.; Meyer, T.; Gray, N. Chemical and biological profile of dual Ckd1 and Cdk2 inhibitors. Curr. Med. Chem.: Anti-Cancer Agents 2003, 3(1), 1-14.
58. (b) Zimmermann, J. Pharmacologically active pyridine derivatives and processes for the preparation thereof. PCT Int. Pat. 1995, WO 9509853.
59. (a) Thornber, C. W. Isosterism and molecular modification in drug design. Chem. Soc. Rev. 1979, 8, 563-580.
60. (b) Horwell, D. C.; Nichols, P. D.; Roberts, E. Methionine replacements in biologically active peptides. Bioorg. Med. Chem. Lett. 1994, 4, 2263-2266.
61. Brogi, E.; Wu, T.; Namiki, A.; Isner, J. M. Indirect angiogenic cytokines upregulate VEGF and bFGF gene expression in vascular smooth muscle cells, whereas hypoxia upregulates VEGF expression only. Circulation 1994, 90, 649-652.
62. Kilic, T.; Alberta, J. A.; Zdunek, P. R.; Acar, M.; Iannarelli, P.; O'Reilly, T.; Buchdunger, E.; Black, P. M.; Stiles, C. D. Intracranial inhibition of platelet-derived growth factor-mediated glioblastoma cell growth by an orally active kinase inhibitor of the 2-phenylaminopyrimidine class. Cancer Res. 2000, 60, 5143-5150.
63. 50 = 0.084 μM) suggests that 15 may inhibit another part of the VEGFR-2 signaling pathway in the stimulated HUVEC cells other than VEGFR-2 inhibition, such as ERK1, FGFR1, Tie2, VEGFR-1.
64. Furet, P.; Zimmermann, J.; Capraro, H.-G.; Meyer, T.; Imbach, P. Structure-based design of potent CDK1 inhibitors derived from olomoucine. J. Comput.-Aided Mol. Des. 2000, 14, 403-409.
65. Emanuel, S.; Gruninger, R. H.; Fuentes-Pesquera, A.; Connolly, P. J.; Seamon, J. A.; Hazel, S.; Tominovich, R.; Hollister, B.; Napier, C.; Reuman, M.; Bignan, G.; Tuman, R.; Johnson, D.; Moffatt, D.; Batchelor, M.; Foley, A.; O'Connell, J.; Allen, R.; Perry, M.; Jolliffe, L.; Middleton, S. A. A VEGF-R2 kinase inhibitor potentiates the activity of the conventional chemotherapeutic agents paclitaxel and doxorubicin in tumor xenograft models. Mol Pharm. 2004, 66, 635-647.
66. McTigue, M. A.; Wickersham, J. A.; Pinko, C.; Showalter, R. E.; Parast, C. V.; Tempczyk-Russell, A.; Gehring, M. R.; Mroczkowski, B.; Kan, C.-C.; Villafranca, J. E.; Appelt, K. Crystal structure of the kinase domain of human vascular endothelial growth factor receptor 2: A key enzyme in angiogenesis. Structure 1999, 7, 319-330.
67. Maestro, Schrodinger, 1500 S. W. First Avenue, Suite 1180, Portland, OR 97201.
68. Still, W. C.; Tempczyk, A.; Hawley, R. C.; Hendrickson, T. Semianalytical treatment of solvation for molecular mechanics and dynamics. J. Am. Chem. Soc. 1990, 112, 6127-6129.
69. Gray, N. S.; Wodicka, L.; Thunnissen, A.-M. W. H.; Norman, T. C.; Kwon, S.; Espinoza, F. H.; Morgan, D. O.; Barnes, G.; LeClerc, S.; Meijer, L.; Kim, S.-H.; Lockhart, D. J.; Schultz, P. G. Exploiting chemical libraries, structure, and genomics in the search for kinase inhibitors. Science 1998, 281, 533-538.
70. Prime, Schrodinger, 1500 S. W. First Avenue, Suite 1180, Portland, OR 97201.
71. Glide, Schrodinger, 1500 S. W. First Avenue, Suite 1180, Portland, OR 97201.
72. Friesner, R. A.; Banks, J. L.; Murphy, R. B.; Halgren, T. A.; Klicic, J. J.; Mainz, D. T.; Repasky, M. P.; Knoll, E. H.; Shelley, M.; Perry, J. K.; Shaw, D. E.; Francis, P.; Shenkin, P. S. Glide: A new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy. J. Med. Chem. 2004, 47, 1739-1749.
73. MacroModel, Schrodinger, 1500 S. W. First Avenue, Suite 1180, Portland, OR 97201.
74. Jorgensen, W. L.; Maxwell, D. S.; Tirado-Rives, J. Development and testing of the OPLS all-atom force field on conformational energetics and properties of organic liquids. J. Am. Chem. Soc. 1996, 118, 11225-11235.